The NADA stated that Paul has been able to prove that his dope violation was "not intentional". The regulatory body has directed the All India Football Federation to take action against the national team doctor.
The dope sample of Paul was collected on March 18 during an out-of-competition test in Mumbai by NADA.
His sample tested positive in National Dope Testing Laboratory (NDTL) for the presence of prohibited substance - Terbutaline (Beta-2-Agonist) - as per the WADA prohibited list 2017.
ADDP conducted hearings on May 31 and June 6.
The disciplinary panel had some strong words for the AIFF, which had been negligent in providing proper guidelines for its players.
The panel has suggested action against the Indian team doctor.
"The doctor during his appearance before the panel had admitted in writing that he failed to take due care in prescribing the medicine to the athlete which led to his ingestion of prohibited substance. The federation has been directed to take necessary action against the team doctor," the release stated.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
